CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
MIAMI, Nov. 03, 2016 -- OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three months ended September 30, 2016, after the close of the U.S. financial markets on Monday, November 7, 2016.
OPKO’s senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, November 7, 2016.
The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, November 7, 2016, 4:30 p.m. ET
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 12830677
For those unable to participate in the conference call or webcast, a replay will be available beginning November 7, 2016 at 7:30 p.m. ET for a period of time. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 12830677.
The replay can also be accessed for a period of time on OPKO’s website at www.opko.com.
About OPKO Health
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the third-largest clinical laboratory in the U.S. with a core genetic testing business and a 420 person sales force to drive growth and sell new products, such as the 4Kscore prostate cancer test and the Claros 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for stage 3-4 CKD patients with secondary hyperparathyroidism and vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics products under development are hGH-CTP, a once weekly human growth hormone for injection (partnered with Pfizer), long acting Factor VIIa for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). OPKO has production and distribution assets in several countries abroad, strategic investments and an active business development strategy. More information is available at www.opko.com.
OPKO Health, Inc.
Company
305-575-4100
Investor Relations
or
Media
Rooney Partners
Terry Rooney, 212-223-0689
[email protected]
or
Marion Janic, 212-223-4017
[email protected]
or
Investors
LHA
Anne Marie Fields, 212-838-3777
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]
